IFRX - InflaRx N.V.
NASDAQ
->
Healthcare
->
Biotechnology
Jena,
Germany
Type: Equity
IFRX price evolution
IFRX
| (in millions $) | 29 Sep 2022 | 29 Jun 2022 | 30 Mar 2022 | 30 Dec 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $17.98 | $15.42 | $40.1 | $26.25 |
| Short term investments | $5.95 | $8.26 | $49.93 | $57.16 |
| Net receivables | $1.59 | $1.52 | $1.15 | $1.28 |
| Inventory | ||||
| Total current assets | $108.73 | $112.13 | $103.7 | $95.68 |
| Long term investments | $0.24 | $0.24 | $9.27 | $27.21 |
| Property, plant & equipment | $1.63 | $1.74 | $1.57 | $1.68 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $111.12 | $114.63 | $115.08 | $125.14 |
| Current liabilities | ||||
| Accounts payable | $7.44 | $7.91 | $9.5 | $1.69 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $10.56 | $11.29 | $18.95 | $18.76 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $11.68 | $12.5 | $19.96 | $19.86 |
| Shareholders' equity | ||||
| Retained earnings | -$235.43 | -$227.51 | -$227.98 | -$213.98 |
| Other shareholder equity | $49.26 | $44.03 | $37.48 | $33.64 |
| Total shareholder equity | $99.44 | $102.13 | $95.12 | $105.28 |
| (in millions $) | 30 Dec 2021 | 30 Dec 2020 | 30 Dec 2019 | 30 Dec 2018 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $26.25 | $25.97 | $33.13 | $55.39 |
| Short term investments | $57.16 | $55.16 | $82.35 | $101.18 |
| Net receivables | $1.28 | $1.42 | $1.13 | |
| Inventory | ||||
| Total current assets | $95.68 | $86.28 | $118.99 | $158.16 |
| Long term investments | $27.21 | $0.27 | $0.27 | $0.21 |
| Property, plant & equipment | $1.68 | $0.95 | $1.41 | $0.62 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $125.14 | $88.22 | $121.58 | $159.21 |
| Current liabilities | ||||
| Accounts payable | $1.69 | $1.74 | $3.35 | $6.66 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $18.76 | $10.1 | $14.06 | $7.76 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $19.86 | $10.35 | $14.43 | $7.82 |
| Shareholders' equity | ||||
| Retained earnings | -$213.98 | -$168.35 | -$134.36 | -$81.11 |
| Other shareholder equity | $33.64 | $22.53 | $27.37 | $18.36 |
| Total shareholder equity | $105.28 | $77.86 | $107.15 | $151.39 |
| (in millions $) | 29 Sep 2022 | 29 Jun 2022 | 30 Mar 2022 | 30 Dec 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $7.54 | $11.18 | $10.47 | $10.13 |
| Selling, general & administrative | $3.09 | $4.35 | $4.39 | $2.87 |
| Total operating expenses | $10.61 | $1.09 | $14.86 | $13 |
| Operating income | -$10.61 | -$1.09 | -$14.86 | -$13 |
| Income from continuing operations | ||||
| EBIT | -$10.61 | -$1.09 | -$14.86 | -$13 |
| Income tax expense | ||||
| Interest expense | -$0.01 | -$0.01 | -$0.02 | -$0.01 |
| Net income | ||||
| Net income | -$7.92 | $0.47 | -$14 | -$12.67 |
| Income (for common shares) | -$7.92 | $0.47 | -$14 | -$12.67 |
| (in millions $) | 30 Dec 2021 | 30 Dec 2020 | 30 Dec 2019 | 30 Dec 2018 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $35.7 | $25.68 | $44.58 | $25.03 |
| Selling, general & administrative | $11.98 | $8.47 | $12.5 | $12.79 |
| Total operating expenses | $47.63 | $33.94 | $56.77 | $37.52 |
| Operating income | -$47.63 | -$33.94 | -$56.77 | -$37.52 |
| Income from continuing operations | ||||
| EBIT | -$47.63 | -$33.94 | -$56.77 | -$37.52 |
| Income tax expense | ||||
| Interest expense | -$0.02 | -$0.03 | -$0.02 | -$0.02 |
| Net income | ||||
| Net income | -$45.63 | -$33.98 | -$53.25 | -$29.81 |
| Income (for common shares) | -$45.63 | -$33.98 | -$53.25 | -$29.81 |
| (in millions $) | 29 Sep 2022 | 29 Jun 2022 | 30 Mar 2022 | 30 Dec 2021 |
|---|---|---|---|---|
| Net income | -$7.92 | $0.47 | -$14 | -$12.67 |
| Operating activities | ||||
| Depreciation | $0.15 | $0.15 | $0.15 | $0.05 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$3.17 | -$12.5 | -$12.86 | -$11.72 |
| Investing activities | ||||
| Capital expenditures | -$0.01 | -$0 | -$0.01 | -$0.02 |
| Investments | $5.01 | -$13.93 | $26.49 | -$33.65 |
| Total cash flows from investing | $5 | -$13.93 | $26.48 | -$33.67 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | -$0.09 | -$0.09 | -$0.09 | -$0.09 |
| Total cash flows from financing | -$0.09 | -$0.09 | -$0.09 | -$0.04 |
| Effect of exchange rate | $0.82 | $1.84 | $0.31 | $1.71 |
| Change in cash and equivalents | $2.56 | -$24.68 | $13.85 | -$43.72 |
| (in millions $) | 30 Dec 2021 | 30 Dec 2020 | 30 Dec 2019 | 30 Dec 2018 |
|---|---|---|---|---|
| Net income | -$45.63 | -$33.98 | -$53.25 | -$29.81 |
| Operating activities | ||||
| Depreciation | $0.55 | $0.58 | $0.56 | $0.17 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$39.94 | -$36.53 | -$43.2 | -$21.55 |
| Investing activities | ||||
| Capital expenditures | -$0.04 | -$0.09 | -$0.59 | -$0.81 |
| Investments | -$25.91 | $21.46 | $20.94 | -$98.64 |
| Total cash flows from investing | -$25.95 | $21.36 | $20.34 | -$99.45 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | -$0.36 | -$0.37 | -$0.3 | -$0.3 |
| Total cash flows from financing | $61.58 | $9.17 | -$0.29 | $49.64 |
| Effect of exchange rate | $4.59 | -$1.17 | $0.9 | $3.46 |
| Change in cash and equivalents | $0.28 | -$7.16 | -$22.25 | -$67.9 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$39.06M |
| EBIT | -$39.55M |
| Net Income | -$34.13M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | -29.30% |
| ROE | -33.96% |
| Debt/Equity | 0.19 |
|---|---|
| Net debt/EBITDA | 0.16 |
| Current ratio | 10.30 |
| Quick ratio | N/A |